India
· Delayed Price · Currency is INR Concord Biotech Statistics
Total Valuation
Concord Biotech has a market cap or net worth of INR 222.76 billion. The enterprise value is 219.96 billion.
| Market Cap | 222.76B |
| Enterprise Value | 219.96B |
Important Dates
The next estimated earnings date is Monday, February 10, 2025.
| Earnings Date | Feb 10, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.05% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 24.88M |
Valuation Ratios
The trailing PE ratio is 67.93.
| PE Ratio | 67.93 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 14.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 47.19, with an EV/FCF ratio of 113.45.
| EV / Earnings | 67.08 |
| EV / Sales | 20.26 |
| EV / EBITDA | 47.19 |
| EV / EBIT | 53.33 |
| EV / FCF | 113.45 |
Financial Position
The company has a current ratio of 6.60, with a Debt / Equity ratio of 0.00.
| Current Ratio | 6.60 |
| Quick Ratio | 4.43 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | 0.02 |
| Interest Coverage | 319.22 |
Financial Efficiency
Return on equity (ROE) is 22.27% and return on invested capital (ROIC) is 17.39%.
| Return on Equity (ROE) | 22.27% |
| Return on Assets (ROA) | 15.58% |
| Return on Capital (ROIC) | 17.39% |
| Revenue Per Employee | 7.88M |
| Profits Per Employee | 2.38M |
| Employee Count | 1,377 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 1.17 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +60.52% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +60.52% |
| 50-Day Moving Average | 1,981.04 |
| 200-Day Moving Average | 1,721.21 |
| Relative Strength Index (RSI) | 54.90 |
| Average Volume (20 Days) | 5,095 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Concord Biotech had revenue of INR 10.86 billion and earned 3.28 billion in profits. Earnings per share was 31.35.
| Revenue | 10.86B |
| Gross Profit | 8.10B |
| Operating Income | 4.13B |
| Pretax Income | 4.42B |
| Net Income | 3.28B |
| EBITDA | 4.65B |
| EBIT | 4.13B |
| Earnings Per Share (EPS) | 31.35 |
Balance Sheet
The company has 2.84 billion in cash and 34.24 million in debt, giving a net cash position of 2.80 billion.
| Cash & Cash Equivalents | 2.84B |
| Total Debt | 34.24M |
| Net Cash | 2.80B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 15.90B |
| Book Value Per Share | 151.99 |
| Working Capital | 7.93B |
Cash Flow
In the last 12 months, operating cash flow was 2.99 billion and capital expenditures -1.06 billion, giving a free cash flow of 1.94 billion.
| Operating Cash Flow | 2.99B |
| Capital Expenditures | -1.06B |
| Free Cash Flow | 1.94B |
| FCF Per Share | n/a |
Margins
Gross margin is 74.57%, with operating and profit margins of 38.06% and 30.20%.
| Gross Margin | 74.57% |
| Operating Margin | 38.06% |
| Pretax Margin | 40.68% |
| Profit Margin | 30.20% |
| EBITDA Margin | 42.85% |
| EBIT Margin | 38.06% |
| FCF Margin | 17.86% |
Dividends & Yields
Concord Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 27.91% |
| Buyback Yield | 0.05% |
| Shareholder Yield | 0.05% |
| Earnings Yield | 1.47% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |